Cargando…
HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma
Low-grade and secondary high-grade gliomas frequently contain mutations in the IDH1 or IDH2 metabolic enzymes that are hypothesized to drive tumorigenesis by inhibiting many of the chromatin-regulating enzymes that regulate DNA structure. Histone deacetylase inhibitors are promising anti-cancer agen...
Autores principales: | Garrett, Matthew C., Albano, Rebecca, Carnwath, Troy, Elahi, Lubayna, Behrmann, Catherine A., Pemberton, Merissa, Woo, Daniel, O’Brien, Eric, VanCauwenbergh, Brett, Perentesis, John, Shah, Sanjit, Hagan, Matthew, Kendler, Ady, Zhao, Chuntao, Paranjpe, Aditi, Roskin, Krishna, Kornblum, Harley, Plas, David R., Lu, Q. Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394035/ https://www.ncbi.nlm.nih.gov/pubmed/37528157 http://dx.doi.org/10.1038/s41598-023-33889-3 |
Ejemplares similares
-
Chromatin structure predicts survival in glioma patients
por: Garrett, Matthew C., et al.
Publicado: (2022) -
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021) -
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014) -
Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
por: Huang, Renhong, et al.
Publicado: (2018) -
Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)